N-(2-tert-butoxybenzyl)-3-(4-phenylpiperidin-1-yl)-N-(pyridin-2-ylmethyl)propan-1-amine → 2-(((3-(4-Phenylpiperidin-1-yl)propyl)(pyridin-2-ylmethyl)amino)methyl)phenol
反応式
C([O:5][C:6]1[CH:35]=[CH:34][CH:33]=[CH:32][C:7]=1[CH2:8][N:9]([CH2:25][C:26]1[CH:31]=[CH:30][CH:29]=[CH:28][N:27]=1)[CH2:10][CH2:11][CH2:12][N:13]1[CH2:18][CH2:17][CH:16]([C:19]2[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=2)[CH2:15][CH2:14]1)(C)(C)C>CCOC(C)=O.Cl>[C:19]1([CH:16]2[CH2:15][CH2:14][N:13]([CH2:12][CH2:11][CH2:10][N:9]([CH2:8][C:7]3[CH:32]=[CH:33][CH:34]=[CH:35][C:6]=3[OH:5])[CH2:25][C:26]3[CH:31]=[CH:30][CH:29]=[CH:28][N:27]=3)[CH2:18][CH2:17]2)[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=1参加物
4
実験手順
Compound 20 (0.15 g, 0.31 mmol) was dissolved in 25 mL EtOAc saturated with HCl and stirred for 3 hr. The solvent was evaporated to dryness. The residue was purified on a silica gel TLC plate that was developed in 8% methanolic NH3 (7 M NH3 in methanol/92% CH2Cl2. The product was obtained as white solid (92%). 1H NMR (CDCl3) δ 8.589 (dd, 1H, Ar), 7.675 (ddd, 1H, Ar), 7.332 (d, 1H, Ar), 7.289 (ddd, 3H, Ar), 7.189 (m, 5H, Ar), 7.009 (dd, 1H, Ar), 6.854 (dd, 1H, Ar), 6.780 (ddd, 1H, Ar), 3.843 (s, 2H, —CH2—), 3.798, (s, 2H, —CH2—), 2.974 (d, 2H, —CH2—), 2.633 (t, 2H, —CH2—), 2.458 (m, 1H, —CH—), 2.333 (m, 2H, —CH2—), 2.000 (m, 2H, —CH2—), 1.782 (m (br), 6H). Mass Spec.=416.27 (M+H)+.